Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.2 DKK | -0.18% | +1.44% | -17.92% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.94 for the current year.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.92% | 4.56B | B- | ||
+14.88% | 69.91B | C+ | ||
+2.42% | 25.14B | C+ | ||
+5.62% | 8.32B | C | ||
+6.10% | 8.07B | B | ||
-20.43% | 7.97B | B- | ||
+17.40% | 4.31B | B+ | ||
-2.00% | 3.99B | B- | ||
-2.47% | 3.87B | B | ||
+21.03% | 3.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLUN B Stock
- LUN Stock
- Ratings Lundbeck